PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 34235123-11 2021 There were statistically significant differences in the frequencies of the HLA-B*38:02 (OR, 10.24; p = 0.0145; 95% CI, 1.09-96.14) and HLA-B*58:01 (OR, 3.98; p = 0.0348; 95% CI, 1.03-15.39) between iopromide-induced immediate hypersensitivity and control. iopromide 198-207 major histocompatibility complex, class I, B Homo sapiens 75-80 34235123-11 2021 There were statistically significant differences in the frequencies of the HLA-B*38:02 (OR, 10.24; p = 0.0145; 95% CI, 1.09-96.14) and HLA-B*58:01 (OR, 3.98; p = 0.0348; 95% CI, 1.03-15.39) between iopromide-induced immediate hypersensitivity and control. iopromide 198-207 major histocompatibility complex, class I, B Homo sapiens 135-140 34235123-12 2021 The mechanism of ICM-induced hypersensitivity remains unknown, but this study showed associations, although weak, with HLA-B*58:01 alleles for ICM-induced immediate hypersensitivity and HLA-B*38:02 and HLA-B*58:01 for iopromide-induced immediate hypersensitivity as risk predictors. iopromide 218-227 major histocompatibility complex, class I, B Homo sapiens 202-207 32741313-6 2021 Our studies have identified six potential inhibitors of Mpro enzyme, out of which four are commercially available FDA approved drugs (Cobicistat, Iopromide, Cangrelor, and Fortovase) and two are from Specs database of natural compounds (Hopeaphenol and Cyclosieversiodide-A). iopromide 146-155 NEWENTRY Severe acute respiratory syndrome-related coronavirus 56-60 2692667-3 1989 The 24-h urinary excretion of the retinol-binding protein (a marker of low molecular weight or tubular proteinuria) and the folate binding protein, a protein localized in the brush-border membranes of the proximal tubular cells, showed a statistically significant transient increase the day after diatrizoate injection, whereas no increase was observed after iopromide. iopromide 359-368 folate receptor alpha Homo sapiens 124-146 32424239-6 2020 Moreover, pretreatment of rats with recombinant human MG53 protein (rhMG53, 2 mg/mL) alleviated iopromide-induced injury in the kidney, which was determined by measuring serum creatinine, blood urea nitrogen and renal histological changes. iopromide 96-105 tripartite motif containing 72 Homo sapiens 54-58 32424239-8 2020 Mechanistically, MG53 translocated to the injury site on RPT cells and bound to phosphatidylserine to protect RPT cells from iopromide-induced injury. iopromide 125-134 tripartite motif containing 72 Homo sapiens 17-21 2568817-3 1989 Among the kidney-specific enzymes, the excretion of GGT in urine increased after injection of iopromide and iopamidol. iopromide 94-103 inactive glutathione hydrolase 2 Homo sapiens 52-55 2568817-4 1989 The maximum increase of GGT excretion was, however, statistically significantly lower in the group treated with iopromide than in the iopamidol group. iopromide 112-121 inactive glutathione hydrolase 2 Homo sapiens 24-27 28874655-5 2017 RESULTS After 24 hours, serum NGAL increase of >=25% was noticed in 32.6% of the patients in the iopromide group and in 25.45% of the patients in the gadolinium group, with significantly higher average percent of this increase in first group (62.23% vs. 36.44%, p=0.002). iopromide 100-109 lipocalin 2 Homo sapiens 30-34 31917760-3 2020 For each patient, 1 mL of iopromide (to determine glomerular filtration rate [GFR]) was coadministered with Gd-EOB-DTPA (Gd-A and Gd-B; 65:35 wt/wt). iopromide 26-35 guanine deaminase Homo sapiens 121-125 31763675-0 2019 DDAH-2 alleviates contrast medium iopromide-induced acute kidney injury through nitric oxide synthase. iopromide 34-43 dimethylarginine dimethylaminohydrolase 2 Mus musculus 0-6 31763675-0 2019 DDAH-2 alleviates contrast medium iopromide-induced acute kidney injury through nitric oxide synthase. iopromide 34-43 nitric oxide synthase 1, neuronal Mus musculus 80-101 28783915-4 2017 Erythromycin, cyprofloxacin and iopromide also increased rapidly up to tens of ngL-1 within a few days. iopromide 32-41 leucine rich repeat containing 4C Homo sapiens 79-84 31998952-4 2020 In vivo and in vitro, IOP treatment caused renal damage and elevated the caspase-1 (+) PI (+) cell count, interleukin (IL)-1b and IL-18 levels, lactate dehydrogenase (LDH) release, and the relative expression of nucleotide-binding domain, leucine-rich repeat containing protein 3 (NLRP3), apoptosis-associated speck-like protein (ASC), and gasdermin D (GSDMD), suggesting that IOP induces AKI via the activation of pyroptosis. iopromide 22-25 interleukin 1 beta Homo sapiens 106-125 31998952-4 2020 In vivo and in vitro, IOP treatment caused renal damage and elevated the caspase-1 (+) PI (+) cell count, interleukin (IL)-1b and IL-18 levels, lactate dehydrogenase (LDH) release, and the relative expression of nucleotide-binding domain, leucine-rich repeat containing protein 3 (NLRP3), apoptosis-associated speck-like protein (ASC), and gasdermin D (GSDMD), suggesting that IOP induces AKI via the activation of pyroptosis. iopromide 22-25 interleukin 18 Homo sapiens 130-135 31998952-4 2020 In vivo and in vitro, IOP treatment caused renal damage and elevated the caspase-1 (+) PI (+) cell count, interleukin (IL)-1b and IL-18 levels, lactate dehydrogenase (LDH) release, and the relative expression of nucleotide-binding domain, leucine-rich repeat containing protein 3 (NLRP3), apoptosis-associated speck-like protein (ASC), and gasdermin D (GSDMD), suggesting that IOP induces AKI via the activation of pyroptosis. iopromide 22-25 leucine rich repeat containing 3 Homo sapiens 239-279 31998952-4 2020 In vivo and in vitro, IOP treatment caused renal damage and elevated the caspase-1 (+) PI (+) cell count, interleukin (IL)-1b and IL-18 levels, lactate dehydrogenase (LDH) release, and the relative expression of nucleotide-binding domain, leucine-rich repeat containing protein 3 (NLRP3), apoptosis-associated speck-like protein (ASC), and gasdermin D (GSDMD), suggesting that IOP induces AKI via the activation of pyroptosis. iopromide 22-25 NLR family pyrin domain containing 3 Homo sapiens 281-286 31998952-4 2020 In vivo and in vitro, IOP treatment caused renal damage and elevated the caspase-1 (+) PI (+) cell count, interleukin (IL)-1b and IL-18 levels, lactate dehydrogenase (LDH) release, and the relative expression of nucleotide-binding domain, leucine-rich repeat containing protein 3 (NLRP3), apoptosis-associated speck-like protein (ASC), and gasdermin D (GSDMD), suggesting that IOP induces AKI via the activation of pyroptosis. iopromide 22-25 PYD and CARD domain containing Homo sapiens 289-328 31998952-4 2020 In vivo and in vitro, IOP treatment caused renal damage and elevated the caspase-1 (+) PI (+) cell count, interleukin (IL)-1b and IL-18 levels, lactate dehydrogenase (LDH) release, and the relative expression of nucleotide-binding domain, leucine-rich repeat containing protein 3 (NLRP3), apoptosis-associated speck-like protein (ASC), and gasdermin D (GSDMD), suggesting that IOP induces AKI via the activation of pyroptosis. iopromide 22-25 PYD and CARD domain containing Homo sapiens 330-333 31998952-4 2020 In vivo and in vitro, IOP treatment caused renal damage and elevated the caspase-1 (+) PI (+) cell count, interleukin (IL)-1b and IL-18 levels, lactate dehydrogenase (LDH) release, and the relative expression of nucleotide-binding domain, leucine-rich repeat containing protein 3 (NLRP3), apoptosis-associated speck-like protein (ASC), and gasdermin D (GSDMD), suggesting that IOP induces AKI via the activation of pyroptosis. iopromide 22-25 gasdermin D Homo sapiens 340-351 31998952-4 2020 In vivo and in vitro, IOP treatment caused renal damage and elevated the caspase-1 (+) PI (+) cell count, interleukin (IL)-1b and IL-18 levels, lactate dehydrogenase (LDH) release, and the relative expression of nucleotide-binding domain, leucine-rich repeat containing protein 3 (NLRP3), apoptosis-associated speck-like protein (ASC), and gasdermin D (GSDMD), suggesting that IOP induces AKI via the activation of pyroptosis. iopromide 22-25 gasdermin D Homo sapiens 353-358 25585347-0 2015 Iopromide in combination with IFN-gamma induces the activation of HMC-1 cells via IL-4 and MCP-1 expression. iopromide 0-9 interleukin 4 Homo sapiens 82-86 28854431-9 2017 RESULTS: Iopromide caused elevation of SCr, BUN and NGAL level, decrease of endogenous creatinine clearance, morphological injury and tubular apoptosis, enhanced IL-1beta and IL-18 expression, and increased expression of S100A8/A9, TLR4 and NLRP3 inflammsome. iopromide 9-18 lipocalin 2 Rattus norvegicus 52-56 28854431-9 2017 RESULTS: Iopromide caused elevation of SCr, BUN and NGAL level, decrease of endogenous creatinine clearance, morphological injury and tubular apoptosis, enhanced IL-1beta and IL-18 expression, and increased expression of S100A8/A9, TLR4 and NLRP3 inflammsome. iopromide 9-18 interleukin 1 beta Rattus norvegicus 162-170 28854431-9 2017 RESULTS: Iopromide caused elevation of SCr, BUN and NGAL level, decrease of endogenous creatinine clearance, morphological injury and tubular apoptosis, enhanced IL-1beta and IL-18 expression, and increased expression of S100A8/A9, TLR4 and NLRP3 inflammsome. iopromide 9-18 interleukin 18 Rattus norvegicus 175-180 28854431-9 2017 RESULTS: Iopromide caused elevation of SCr, BUN and NGAL level, decrease of endogenous creatinine clearance, morphological injury and tubular apoptosis, enhanced IL-1beta and IL-18 expression, and increased expression of S100A8/A9, TLR4 and NLRP3 inflammsome. iopromide 9-18 S100 calcium binding protein A8 Rattus norvegicus 221-230 28854431-9 2017 RESULTS: Iopromide caused elevation of SCr, BUN and NGAL level, decrease of endogenous creatinine clearance, morphological injury and tubular apoptosis, enhanced IL-1beta and IL-18 expression, and increased expression of S100A8/A9, TLR4 and NLRP3 inflammsome. iopromide 9-18 toll-like receptor 4 Rattus norvegicus 232-236 28854431-9 2017 RESULTS: Iopromide caused elevation of SCr, BUN and NGAL level, decrease of endogenous creatinine clearance, morphological injury and tubular apoptosis, enhanced IL-1beta and IL-18 expression, and increased expression of S100A8/A9, TLR4 and NLRP3 inflammsome. iopromide 9-18 NLR family, pyrin domain containing 3 Rattus norvegicus 241-246 28854431-10 2017 In NRK-52E cells, iopromide caused enhanced apoptotic rates and ROS generation, which could be ameliorated by inhibitor of TLR4 and NLRP3-siRNA. iopromide 18-27 toll-like receptor 4 Rattus norvegicus 123-127 28854431-10 2017 In NRK-52E cells, iopromide caused enhanced apoptotic rates and ROS generation, which could be ameliorated by inhibitor of TLR4 and NLRP3-siRNA. iopromide 18-27 NLR family, pyrin domain containing 3 Rattus norvegicus 132-137 25585347-0 2015 Iopromide in combination with IFN-gamma induces the activation of HMC-1 cells via IL-4 and MCP-1 expression. iopromide 0-9 C-C motif chemokine ligand 2 Homo sapiens 91-96 25585347-2 2015 Iopromide, a nonionic iodinated contrast agent, slightly induced mast cell proliferation and significantly increased the expression of IL-4 and MCP-1 at low doses. iopromide 0-9 interleukin 4 Homo sapiens 135-139 25585347-2 2015 Iopromide, a nonionic iodinated contrast agent, slightly induced mast cell proliferation and significantly increased the expression of IL-4 and MCP-1 at low doses. iopromide 0-9 C-C motif chemokine ligand 2 Homo sapiens 144-149 25585347-3 2015 The pretreatment of cells with IFN-gamma dramatically increased the expression of iopromide-induced IL-4 and MCP-1. iopromide 82-91 interferon gamma Mus musculus 31-40 25585347-3 2015 The pretreatment of cells with IFN-gamma dramatically increased the expression of iopromide-induced IL-4 and MCP-1. iopromide 82-91 interleukin 4 Mus musculus 100-104 25585347-3 2015 The pretreatment of cells with IFN-gamma dramatically increased the expression of iopromide-induced IL-4 and MCP-1. iopromide 82-91 mast cell protease 1 Mus musculus 109-114 25585347-4 2015 An evaluation of mast cell activator secretion revealed that IFN-gamma- or IL-4-pretreated HMC-1 cells released dramatically increased levels of beta-hexosaminidase and histamine when stimulated with iopromide. iopromide 200-209 interferon gamma Homo sapiens 61-70 25585347-4 2015 An evaluation of mast cell activator secretion revealed that IFN-gamma- or IL-4-pretreated HMC-1 cells released dramatically increased levels of beta-hexosaminidase and histamine when stimulated with iopromide. iopromide 200-209 interleukin 4 Homo sapiens 75-79 25585347-4 2015 An evaluation of mast cell activator secretion revealed that IFN-gamma- or IL-4-pretreated HMC-1 cells released dramatically increased levels of beta-hexosaminidase and histamine when stimulated with iopromide. iopromide 200-209 O-GlcNAcase Homo sapiens 145-164 25585347-5 2015 We also found that the migration of EoL-1 and THP-1 cells was significantly increased in culture conditions with iopromide-stimulated IL-4-pretreated HMC-1 cells. iopromide 113-122 interleukin 4 Homo sapiens 134-138 16989777-6 2006 The incubation of human renal tubular proximal cells with sodium diatrizoate, iopromide and iomeprol caused a marked dephosphorylation of the kinase Akt on Ser473 within 5min of incubation. iopromide 78-87 AKT serine/threonine kinase 1 Homo sapiens 149-152 25359386-12 2014 Significantly increased expressions of GRP78 and CHOP were observed in the NRK-52E cells exposed to iopromide for 4 h; NAC attenuated iopromide-induced NRK-52E cell apoptosis by inhibiting the overproduction of intracellular ROS and subsequently suppressing the overexpression of GRP78 and CHOP. iopromide 100-109 heat shock protein family A (Hsp70) member 5 Rattus norvegicus 39-44 25359386-12 2014 Significantly increased expressions of GRP78 and CHOP were observed in the NRK-52E cells exposed to iopromide for 4 h; NAC attenuated iopromide-induced NRK-52E cell apoptosis by inhibiting the overproduction of intracellular ROS and subsequently suppressing the overexpression of GRP78 and CHOP. iopromide 100-109 DNA-damage inducible transcript 3 Rattus norvegicus 49-53 25359386-12 2014 Significantly increased expressions of GRP78 and CHOP were observed in the NRK-52E cells exposed to iopromide for 4 h; NAC attenuated iopromide-induced NRK-52E cell apoptosis by inhibiting the overproduction of intracellular ROS and subsequently suppressing the overexpression of GRP78 and CHOP. iopromide 100-109 heat shock protein family A (Hsp70) member 5 Rattus norvegicus 280-285 25359386-12 2014 Significantly increased expressions of GRP78 and CHOP were observed in the NRK-52E cells exposed to iopromide for 4 h; NAC attenuated iopromide-induced NRK-52E cell apoptosis by inhibiting the overproduction of intracellular ROS and subsequently suppressing the overexpression of GRP78 and CHOP. iopromide 100-109 DNA-damage inducible transcript 3 Rattus norvegicus 290-294 21039317-1 2011 The aim of this study was to evaluate the computed tomography (CT)-imaging potential of iopromide-carrying liposomes (SPC/CH/SPG, 6:3:1) of approximately 200 nm in diameter in healthy rabbits and in rabbits with implanted liver tumors in an intraindividual comparison with iopromide. iopromide 88-97 pulmonary surfactant-associated protein C Oryctolagus cuniculus 118-121 20412314-7 2011 IL-3 prestimulus revealed a more pronounced CD63 expression after iopromide than after iotrolan. iopromide 66-75 interleukin 3 Homo sapiens 0-4 20412314-7 2011 IL-3 prestimulus revealed a more pronounced CD63 expression after iopromide than after iotrolan. iopromide 66-75 CD63 molecule Homo sapiens 44-48 20458252-14 2010 The angiotensin II dose response curves showed greater reactivity for amidotrizoate, iopromide and iodixanol, when compared with controls. iopromide 85-94 angiotensinogen Rattus norvegicus 4-18 18287437-8 2008 RESULTS: In four patients (suffering from anaphylaxis grades 2 and 3) out of the 96 (4.2%), skin tests and basophil activation tests strongly suggested IgE-mediated allergy to the contrast materials iopromide (two patients), iomeprol, and iopentol. iopromide 199-208 immunoglobulin heavy constant epsilon Homo sapiens 152-155 16989777-10 2006 However there was a more dramatic decrease in phosphorylation of the phosphorylated form of mammalian target of rapamycin (mTOR) and of the extracellular-signal regulated kinases (ERK) 1/2 caused by sodium diatrizoate than by iopromide. iopromide 226-235 mechanistic target of rapamycin kinase Homo sapiens 92-121 16989777-10 2006 However there was a more dramatic decrease in phosphorylation of the phosphorylated form of mammalian target of rapamycin (mTOR) and of the extracellular-signal regulated kinases (ERK) 1/2 caused by sodium diatrizoate than by iopromide. iopromide 226-235 mechanistic target of rapamycin kinase Homo sapiens 123-127 16989777-10 2006 However there was a more dramatic decrease in phosphorylation of the phosphorylated form of mammalian target of rapamycin (mTOR) and of the extracellular-signal regulated kinases (ERK) 1/2 caused by sodium diatrizoate than by iopromide. iopromide 226-235 mitogen-activated protein kinase 3 Homo sapiens 140-188 16602274-10 2006 In the second in vitro study, we made sequential dilutions of iopromide (Ultravist; Schering) with serum to explore their potential for interfering with the detection of cTnI by the Opus Magnum and ACCESS assays. iopromide 62-71 troponin I3, cardiac type Homo sapiens 170-174 15982481-6 2005 CysC showed higher non-parametric correlation (r=0.805) to the iopromide clearance compared to crea (r=0.652) and to the estimated GFR according to the Cockcroft-Gault formula (r=0.690), which underestimated true GFR systematically. iopromide 63-72 cystatin C Homo sapiens 0-4 15982481-8 2005 At a cut-off level of >1.3 mg/l cysC exhibited an 88% sensitivity and a 96% specificity for detecting renal dysfunction which was defined as an iopromide clearance less than 80 ml/min/1.73 m2; best values for crea were 63% for sensitivity and 80% for specificity at a cut-off of >1.2 mg/dl. iopromide 147-156 cystatin C Homo sapiens 35-39 16372478-0 2005 Angiopoietin-1 reduces iopromide-induced endothelial cell apoptosis through activation of phosphatidylinositol 3"-kinase/p70 S6 kinase. iopromide 23-32 angiopoietin 1 Homo sapiens 0-14 16372478-0 2005 Angiopoietin-1 reduces iopromide-induced endothelial cell apoptosis through activation of phosphatidylinositol 3"-kinase/p70 S6 kinase. iopromide 23-32 ubiquitin associated and SH3 domain containing B Homo sapiens 121-124 16372478-4 2005 The present study evaluated whether the radiocontrast agent iopromide induces apoptosis in human umbilical vein endothelial cells and also whether angiopoietin-1 (Ang1) protects against iopromide-induced apoptosis through the p70 S6 kinase-dependent signaling pathway. iopromide 186-195 angiopoietin 1 Homo sapiens 147-161 16372478-4 2005 The present study evaluated whether the radiocontrast agent iopromide induces apoptosis in human umbilical vein endothelial cells and also whether angiopoietin-1 (Ang1) protects against iopromide-induced apoptosis through the p70 S6 kinase-dependent signaling pathway. iopromide 186-195 angiopoietin 1 Homo sapiens 163-167 16372478-6 2005 Ang1 reduced iopromide-induced apoptosis in a dose-dependent manner. iopromide 13-22 angiopoietin 1 Homo sapiens 0-4 16372478-10 2005 These results suggest that Ang1 may protect vascular endothelial cells from iopromide-induced apoptosis through phosphatidylinositol 3"-kinase and mTOR/S6 kinase. iopromide 76-85 angiopoietin 1 Homo sapiens 27-31 16372478-10 2005 These results suggest that Ang1 may protect vascular endothelial cells from iopromide-induced apoptosis through phosphatidylinositol 3"-kinase and mTOR/S6 kinase. iopromide 76-85 mechanistic target of rapamycin kinase Homo sapiens 147-151 7797411-8 1995 RESULTS: Iopromide substantially increased atrial natriuretic peptide (48.8 +/- 8.9 to 85.8 +/- 13.0) and antidiuretic hormone (3.4 +/- 0.3 to 4.6 +/- 0.5) levels, whereas renin decreased (0.9 +/- 0.1 to 0.8 +/- 0.2) slightly but not significantly. iopromide 9-18 arginine vasopressin Homo sapiens 106-126 11294523-11 2001 At the highest iopromide concentration tested, 184 mmol/L, the mean inhibition of thrombin activity was 44.5%. iopromide 15-24 coagulation factor II, thrombin Homo sapiens 82-90 11294523-14 2001 The inhibition of thrombin by iopromide is specific, because trypsin was not inhibited by iopromide. iopromide 30-39 coagulation factor II, thrombin Homo sapiens 18-26 11294523-15 2001 The results indicate that in vitro iopromide at clinically relevant concentrations partially inhibits thrombin activity. iopromide 35-44 coagulation factor II, thrombin Homo sapiens 102-110 10817039-7 2000 Both Iopromide and Ioxaglate caused further increases in thrombin-antithrombin complex, prothrombin fragments 1 + 2 and beta-thromboglobulin. iopromide 5-14 pro-platelet basic protein Homo sapiens 120-140 12759490-3 2003 This coronary angiography study was performed to extend those findings using another nonionic RCM, iopromide, and to further determine whether iopromide causes release of ET-1. iopromide 143-152 endothelin 1 Homo sapiens 171-175 12631011-10 2003 CONCLUSION: In the normal rat, activation of ET-A receptors is partly involved in the depression of outer medullary pO2 caused by injection of iopromide. iopromide 143-152 endothelin receptor type A Rattus norvegicus 45-49 12372925-3 2002 The use of an ionic X-ray contrast agent (XCA) (ioxaglate) in diagnostic cardiac catheterisation angiography is associated with lower thrombin generation and lower activation of the platelet system than when a non-ionic XCA is employed (iopromide). iopromide 237-246 X chromosome controlling element Homo sapiens 42-45 11294523-0 2001 Inhibition of thrombin by iopromide in vitro. iopromide 26-35 coagulation factor II, thrombin Homo sapiens 14-22 11294523-3 2001 The goal of this study was to characterize the interaction of iopromide with thrombin, specifically to determine the rate, extent, specificity, and reversibility of the thrombin inhibition by iopromide, the integrity of the thrombin-iopromide complex, and the inhibitory potency of iopromide using a validated assay methodology. iopromide 62-71 coagulation factor II, thrombin Homo sapiens 77-85 11294523-3 2001 The goal of this study was to characterize the interaction of iopromide with thrombin, specifically to determine the rate, extent, specificity, and reversibility of the thrombin inhibition by iopromide, the integrity of the thrombin-iopromide complex, and the inhibitory potency of iopromide using a validated assay methodology. iopromide 62-71 coagulation factor II, thrombin Homo sapiens 169-177 11294523-3 2001 The goal of this study was to characterize the interaction of iopromide with thrombin, specifically to determine the rate, extent, specificity, and reversibility of the thrombin inhibition by iopromide, the integrity of the thrombin-iopromide complex, and the inhibitory potency of iopromide using a validated assay methodology. iopromide 62-71 coagulation factor II, thrombin Homo sapiens 169-177 11294523-3 2001 The goal of this study was to characterize the interaction of iopromide with thrombin, specifically to determine the rate, extent, specificity, and reversibility of the thrombin inhibition by iopromide, the integrity of the thrombin-iopromide complex, and the inhibitory potency of iopromide using a validated assay methodology. iopromide 192-201 coagulation factor II, thrombin Homo sapiens 169-177 11294523-3 2001 The goal of this study was to characterize the interaction of iopromide with thrombin, specifically to determine the rate, extent, specificity, and reversibility of the thrombin inhibition by iopromide, the integrity of the thrombin-iopromide complex, and the inhibitory potency of iopromide using a validated assay methodology. iopromide 192-201 coagulation factor II, thrombin Homo sapiens 169-177 11294523-3 2001 The goal of this study was to characterize the interaction of iopromide with thrombin, specifically to determine the rate, extent, specificity, and reversibility of the thrombin inhibition by iopromide, the integrity of the thrombin-iopromide complex, and the inhibitory potency of iopromide using a validated assay methodology. iopromide 192-201 coagulation factor II, thrombin Homo sapiens 169-177 11294523-3 2001 The goal of this study was to characterize the interaction of iopromide with thrombin, specifically to determine the rate, extent, specificity, and reversibility of the thrombin inhibition by iopromide, the integrity of the thrombin-iopromide complex, and the inhibitory potency of iopromide using a validated assay methodology. iopromide 192-201 coagulation factor II, thrombin Homo sapiens 169-177 11294523-5 2001 The final concentrations of iopromide in the presence of estimated physiologic concentrations of thrombin (1 nmol/L) were 0-184 mmol/L. iopromide 28-37 coagulation factor II, thrombin Homo sapiens 97-105 11294523-7 2001 The possible inhibition of the protease trypsin by iopromide was investigated to evaluate the specificity of thrombin inhibition by iopromide. iopromide 132-141 coagulation factor II, thrombin Homo sapiens 109-117 11294523-9 2001 The inhibition of thrombin by iopromide was immediate, rapidly reversible, and proportionate to the iopromide concentrations. iopromide 30-39 coagulation factor II, thrombin Homo sapiens 18-26 11294523-9 2001 The inhibition of thrombin by iopromide was immediate, rapidly reversible, and proportionate to the iopromide concentrations. iopromide 100-109 coagulation factor II, thrombin Homo sapiens 18-26 10195004-5 1998 A total dose of 600 mgI kg-1 bw of iodixanol (320 mgI ml-1) or iopromide (300 mgI ml-1) was injected. iopromide 63-72 interleukin 17F Homo sapiens 82-86 8537207-10 1995 RESULTS: Administration of iopromide caused significant increases in atrial natriuretic peptide (from 61.3 +/- 11.8 to 94.0 +/- 16.7) and antidiuretic hormone (from 6.6 +/- 1.9 to 12.3 +/- 3.1), whereas renin significantly decreased (from 3.0 +/- 0.6 to 1.3 +/- 0.5). iopromide 27-36 arginine vasopressin Homo sapiens 138-158 8537207-10 1995 RESULTS: Administration of iopromide caused significant increases in atrial natriuretic peptide (from 61.3 +/- 11.8 to 94.0 +/- 16.7) and antidiuretic hormone (from 6.6 +/- 1.9 to 12.3 +/- 3.1), whereas renin significantly decreased (from 3.0 +/- 0.6 to 1.3 +/- 0.5). iopromide 27-36 renin Homo sapiens 203-208 7797411-8 1995 RESULTS: Iopromide substantially increased atrial natriuretic peptide (48.8 +/- 8.9 to 85.8 +/- 13.0) and antidiuretic hormone (3.4 +/- 0.3 to 4.6 +/- 0.5) levels, whereas renin decreased (0.9 +/- 0.1 to 0.8 +/- 0.2) slightly but not significantly. iopromide 9-18 renin Homo sapiens 172-177 8175303-5 1994 RESULTS: Contrast media enhanced bradykinin-induced pain was dose dependent with the following potency order: iopamidol > iopromide > ZK 139129 > ZK 119095. iopromide 125-134 kininogen 1 Homo sapiens 33-43 7957519-5 1994 The terminal disposition phase half-life of iopromide was 2 h and 1.9 h, and the total clearance was 110 and 103 ml.min-1 at the lower and at the higher dose levels, respectively. iopromide 44-53 CD59 molecule (CD59 blood group) Homo sapiens 116-121 2241536-0 1990 [Comparative study of the binding or iosarcol, iopamidol, iopromide, and iohexol to human serum albumin]. iopromide 58-67 albumin Homo sapiens 96-103 34860739-9 2022 The primary target variable was the risk of HSR to iopromide in children (<18 years) and elderly patients (>=65 years) compared with adults (>=18 to <65 years). iopromide 51-60 HSR Homo sapiens 44-47 34697153-10 2021 CONCLUSION: High concentrations of iopromide induce cell damage, apoptosis, and autophagy through down-regulating AKT and ROS-activated cellular stress pathways in HEK 293 cells. iopromide 35-44 AKT serine/threonine kinase 1 Homo sapiens 114-117